How big is the Insulin Glargine Market?

The Insulin Glargine Market size is expected to reach USD 1.54 billion in 2024 and grow at a CAGR of 6.28% to reach USD 2.09 billion by 2029. Read More

What is the current Insulin Glargine Market size?

In 2024, the Insulin Glargine Market size is expected to reach USD 1.54 billion. Read More

Who are the key players in Insulin Glargine Market?

Sanofi Aventis, Novo Nordisk AS, Biocon, Eli Lilly and Company and Julphar are the major companies operating in the Insulin Glargine Market. Read More

Which is the fastest growing region in Insulin Glargine Market?

North America is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Insulin Glargine Market?

In 2024, the North America accounts for the largest market share in Insulin Glargine Market. Read More

What years does this Insulin Glargine Market cover, and what was the market size in 2023?

In 2023, the Insulin Glargine Market size was estimated at USD 1.45 billion. The report covers the Insulin Glargine Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Insulin Glargine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Insulin Glargine Market

Insulin Glargine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Insulin Glargine Market Trends & Forecast and the market is segmented by type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Insulin Glargine Biosimilars) and geography (North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa). The market provides the value (in USD million) for the above-mentioned segments.

Insulin Glargine Industry Overview

The global insulin glargine market is moderately consolidated, mainly consisting of three major manufacturers (Sanofi, Novo Nordisk, and Eli Lilly) with a global market presence. The remaining manufacturers are confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (insulin glargine), whereas Biocon collaborated with Mylan to develop Semglee (an insulin glargine biosimilar). Prominent players, such as Sanofi, Novo Nordisk, and Lilly, have created a monopoly in the market through their established supply chains and branding, which has resulted in substantial market penetration. These companies work in tandem with several administrative and health agencies to deploy competitive strategies and restrict or eliminate competition from emerging market players.